The Food and Drug Administration regularly reviews drugs for various risk factors. These risk factors include harm to patients and adverse side effects. 

At this time, the FDA has put a black box warning on gadolinium. The FDA may change its policy toward gadolinium depending on future reviews. These reviews often look at recent studies or other reports that relate to gadolinium.

If you or anyone you know has questions about gadolinium, contact the gadolinium attorneys of Williams Kherkher at 800-761-3187.